PCMA’s Call For Action On Drug Costs In Testimony On MTM
This article was originally published in RPM Report
Here is how PCMA President Mark Merritt raised the issue of drug costs in his written testimony submitted for an October 21 hearing on Medication Therapy Management held by the House Energy & Commerce/Health Subcommittee. The issue was not raised during the hearing itself.
Register for our free email digests: